Home » Agenda


Vaccines & Immunogenicity World Congress 2023 Europe

London, United Kingdom

Monday 13th - Tuesday 14th November 2023

Paradigm Global Events is proud to present its Vaccines & Immunogenicity World Congress 2023 Europe. Progress in virology, genetics, synthetic biology, and biotechnology has provided a new set of tools to approach current-day vaccinology, while increased understanding of human immunity and microbes has catalyzed unprecedented advances that can be adopted to improve public health. Despite continuing challenges, the collective effort of governments and nonprofit organizations to expand the utilization of effective vaccines throughout the world has grown.

We are gathering high caliber expert speakers to participate and share their knowledge and expertise through Keynotes, Presentations, and Panel discussions.

We look forward to welcoming you to the Vaccines & Immunogenicity World Congress 2023 Europe

Sincerely yours,

Jocelyn Raguindin
Conference Director
Paradigm Global Events


In the upcoming 2023 Vaccine Congress, dynamic approach to key trends, methodologies and insights on new vaccine platforms for cancer and emerging diseases, manufacturing trends, and regulatory compliance is anticipated. Gain latest insights on:

  • Latest developments on new adjuvant technologies and novel immunotherapies in the treatment of cancer and
    emerging viral diseases
  • Comprehensive insights on new technological developments in vaccine production
  • Regulatory approach and economic consideration on vaccine trials


Network with cancer geneticists, cancer biologists, experts in cancer antigen presentation, tumor immunologists, vaccinologists, senior VPs, Heads, Directors and Managers of leading biopharmaceutical and biotech companies whose
responsibilities include manufacturing, research and development, regulatory and marketing, government and non- government vaccine leads. 

  • Novel vaccination approaches based on rational design of B­ and T­cell epitopes
  • Progress on using recombinant DNA technology, advanced cell­culture technique, immunoinformatics and rational design of immunogens for vaccine


  • Impact of different inactivation and splitting procedures on vaccine composition, stability and recovery to support transfer of process technology
  • Bioreactors for high cell density and continuous multi-stage cultivations as new options for process intensification in cell culture-based viral vaccine production
  • High cell density and continuous multi-stage cultivations as options for process intensification in cell culture-based viral vaccine production
  • Recent developments in establishing new designed cell lines, better host cell metabolism, advances in media design, and the use of mathematical models for process optimization
  • Replication-deficient adenoviruses as potent vaccine development platforms for human candidate vaccines
  • Cellular targets for improved manufacturing of virus-based biopharmaceuticals in animal cells
  • Clarification of vaccines as critical step for product recovery and subsequent downstream purification
  • Comprehensive view on different membrane based technologies and their application in vaccine clarification, challenges and best practice


  • Continued evolution of safety evaluation processes that keep pace with advances in vaccine technology
  • Regulatory aspects relevant to adjuvanted vaccines
  • Summary of lessons learned from completed HIV/AIDS vaccine efficacy trials relevant to regulatory evaluation of clinical trial applications for vaccines in development
  • Challenges regulators face when reviewing clinical trial applications
  • Exploiting the immunogenic potential of cancer cells for improved dendritic cell vaccines
  • Combinations of immuno-stimulatory or immuno-modulatory adjuvants for the development of novel adjuvants for cancer immunotherapy


  • Oncolytic virotherapy and immune checkpoint blockade agents to enhance the anti tumor response
  • Adapting dendritic cell-based vaccine for pancreatic cancer
  • Novel vaccine designs that employ strategies to prevent HIV acquisition and development of therapeutic vaccine
  • Dendritic cell activation and HIV vaccine effectiveness enhanced through nanoparticle vaccination
  • Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine
  • Development of therapeutic antibodies against dengue virus


  • B and T cell epitope-based peptides from conserved and whole protein sequences of Ebola virus as vaccine targets
  • Identification of cell-targeting antibodies in immunity to Ebola
  • Targeting conserved B­ and T­cell epitopes for developing broadly protective or “universal” influenza virus vaccines 
  • Developing quadrivalent virus like particle influenza vaccine from plants
  • Status of vaccine research and development of vaccines for tuberculosis
  • Complement component 3 as new paradigm in tuberculosis vaccine
  • A retrospective analysis of the Alzheimer's disease vaccine progress
  • Focus on amyloid-β, α-synuclein, and tau for the treatment of neurodegenerative disorders
Scroll to Top